Alcanza Clinical Research

What Alcanza Clinical Research does

Alcanza Clinical Research is a privately held, Martis Capital-backed operator of a multi-site clinical research network in the United States and Puerto Rico. Formed in 2021 through the acquisition of three high-performing independent research brands, the company has scaled to 25+ dedicated research units across 11 states plus Puerto Rico, organized around retained sub-brands such as Accel Research, ActivMed, Boston Clinical Trials, Charlottesville Medical Research, Coastal Carolina Research Center, Desert Clinical Research, FDI Clinical Research, Innovation Medical Research, Kansas City Research Institute, North Georgia Clinical Research, Olympus Clinical Research, Phoenix Medical Trials, Quest Research Institute, and Tampa Bay Medical Research. The network conducts Phase I–IV and medical device trials across more than 30 therapeutic areas, supported by 100+ Principal Investigators, 90 Phase 1 inpatient beds across five sites, an aggregated patient database of 850,000+ patients, and centralized Study Delivery, Quality Management, and Patient Recruitment functions. ReachOne AI Toolbox is offered alongside the network as an AI-augmented patient recruitment tool.

The company generates revenue through professional-services fees from pharmaceutical sponsors, biotech companies, and contract research organizations (CROs) that retain Alcanza to execute multi-site trials, including patient enrollment, regulatory compliance, data collection, and site management. Enterprise-level relationships are managed through a centralized Business Development function that serves as a single point of contact for site qualification and escalation; patient recruitment is driven by site-level databases, centralized advertising, phone recruiting, and community/physician referrals. Alcanza is a founding member of the Association of Multisite Research Corporations (AMRC), a 14-member alliance encompassing 400+ research sites, ~1,000 PIs, and 7,000+ research professionals that collectively enrolled 73,500 patients in 2024. The network is privately held under Martis Capital ownership and continues to expand through both acquisitions and de novo site launches.

Name

Alcanza Clinical Research

Legal name

Alcanza Clinical Research Holdings

Website

https://alcanzaclinical.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Alcanza Clinical Research is a Martis Capital-backed operator of a 25+ site clinical research network across 11 US states and Puerto Rico, executing Phase I–IV trials across 30+ therapeutic areas for pharmaceutical sponsors and CROs, supported by 100+ investigators and an 850K+ patient recruitment database.

Ownership category

akta.pro rank

Product category

Clinical Research Site Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Liver & GI Clinical Research (Trials Centers) (HLAKAEAL)

Keywords

• Clinical research services
• Clinical trial site network
• Patient recruitment services
• Investigator site network
• Phase I-IV trials

Headquarters

HQ city

Methuen

HQ country

United States

HQ region

North America

Offices26 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Clinical Trial Services for Sponsors and CROs: Alcanza operates as an investigator site network, executing Phase I-IV clinical trials on behalf of pharmaceutical sponsors, biotech companies, and CROs. Revenue is generated through professional services fees for conducting clinical trials, including patient enrollment, data collection, regulatory compliance, and site management. The network maintains relationships with over 70 pharmaceutical and medical device sponsors.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Alcanza Clinical Research operates a multi-site clinical research site network of 25+ dedicated research units across 11 U.S. states and Puerto Rico, executing Phase I–IV and medical device clinical trials for pharmaceutical, biotech, and medical device sponsors as well as CROs across 30+ therapeutic areas. The network is supported by centralized Study Delivery project management, centralized patient recruitment infrastructure, a centralized Quality Management Plan, and a Diversity, Equity & Inclusion Committee, and offers Phase 1 inpatient capabilities (90 beds across 5 sites). The company also offers the ReachOne AI Toolbox for AI-powered patient recruitment.

Product overview

Alcanza Clinical Research operates a multi-site clinical research site network composed of 25+ owned and affiliated clinical research sites across 11 states plus Puerto Rico. The network is powered by centralized teams and operating procedures including Study Delivery project management, Centralized Recruitment Services, Quality Compliance Framework, and a Diversity, Equity & Inclusion Committee. Individual site brands (Accel Research Sites, ActivMed Research, Boston Clinical Trials, Charlottesville Medical Research, Coastal Carolina Research Center, Desert Clinical Research, FDI Clinical Research, Fredericksburg Clinical Research, Innovation Medical Research Center, Kansas City Research Institute, North Georgia Clinical Research, Olympus Clinical Research, Phoenix Medical Trials, Quest Research Institute, Tampa Bay Medical Research) maintain their original names for community and Sponsor/CRO relationships while benefiting from integrated IT systems and cross-functional workstreams. The company also offers ReachOne AI Toolbox as its patient recruitment technology. Network capabilities span Phase I-IV trials across 30+ therapeutic areas with 850K+ patients in its combined database.

Differentiator

Problem solved

Functional benefit

Brands

• ReachOne AI Toolbox: AI-powered patient recruitment and toolbox platform

Products and services

• Alcanza Clinical Research Network Multi-site clinical research site network of 25+ dedicated research units across 11 U.S. states and Puerto Rico, executing Phase I–IV and medical device clinical trials across 30+ therapeutic areas for pharmaceutical, biotech, and medical device sponsors and CROs. The network provides centralized Study Delivery project management, centralized patient recruitment infrastructure, a Quality Management Plan, Phase 1 inpatient capabilities (90 beds across 5 sites), and access to an 850,000+ patient database.
• ReachOne AI Toolbox AI-powered patient recruitment platform operated by Alcanza that leverages artificial intelligence to support clinical trial enrollment and drive patient engagement outcomes.

Quantifiable outcome

• Active studies grew more than fourfold since the company's formation in 2021
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• AMRC (Association of Multisite Research Corporations)coreStrategic or Co-development PartnerAlcanza is a founding member of AMRC, a newly launched alliance of 14 prominent multisite research organizations. AMRC brings together over 400 research sites, nearly 1,000 Principal Investigators, and 7,000+ research professionals. In 2024, AMRC members collectively enrolled over 73,500 patients into clinical trials. The alliance aims to transform clinical trial conduct in the U.S. by minimizing delays, improving operational efficiency, and strengthening collaboration, standardization, and data quality.
• SCRS (Society for Clinical Research Sites)coreStrategic or Co-development PartnerAlcanza is an active member and thought leader in SCRS, a global organization representing nearly 10,000 clinical research sites in 47 countries. Chief Commercial Officer Casey Orvin served as past President of SCRS, and the company collaborates on industry initiatives to advance the site voice within the clinical research industry.

Scale indicators16 records

Recent moves11 records

Expansion highlights7 records

Broad incumbents

• ICON plc: ICON is a leading global CRO with site-services and decentralized trial capabilities following its PRA Health Sciences merger. It competes with Alcanza for sponsor relationships and multi-site trial execution at the enterprise level.
• Fortrea (formerly LabCorp Drug Development): Fortrea is a global CRO offering end-to-end clinical development services. Its Early Development / site-services footprint overlaps with Alcanza's Phase I–IV offering; Alcanza's CEO Carlos Orantes previously held leadership roles at Covance/LabCorp.
• IQVIA: IQVIA is the world's largest CRO with a substantial site-services and patient-recruitment capability through its Q² Solutions and site-network operations. It is comparable to Alcanza at the enterprise level as a buyer of site capacity and a competitor for multi-site trial contracts.
• Syneos Health: Syneos Health is a top-tier CRO with a Clinical Site Services division. It competes with Alcanza as a comprehensive clinical research services provider and historically operated its own dedicated site network.

Direct peers

• Velocity Clinical Research: Velocity is a leading integrated clinical research site network operating dedicated research sites across the U.S. It competes directly with Alcanza for multi-site Phase I–IV trial awards from pharma sponsors and CROs.
• CenExel: CenExel is one of the largest U.S. clinical research site networks with deep specialization in CNS and other therapeutic areas. It is the most direct comparable to Alcanza's multi-therapeutic, multi-site model — Alcanza's CCO Casey Orvin was previously CCO at CenExel.
• Flourish Research: Flourish Research is a multi-site clinical research organization built through acquisitions of independent sites. It is comparable to Alcanza in its roll-up strategy, therapeutic breadth, and centralized recruitment infrastructure — Alcanza's Executive Director of Patient Recruitment previously led recruitment at Flourish.
• Hassman Research Institute (HRI): HRI is a dedicated multi-specialty clinical research site network conducting Phase I–IV trials. It overlaps with Alcanza's multi-site, multi-therapeutic service offering and competes for similar sponsor business.
• K2 Medical Research: K2 Medical Research is a multi-specialty clinical research site network with strong therapeutic-area breadth. It competes with Alcanza for sponsor and CRO study allocations across Phase I–IV trials. Alcanza's VP of Patient Experience previously served at K2.

Others

• Clincierge: Clincierge is a clinical trial patient logistics and retention services provider serving sponsors, CROs, and sites. It is comparable to Alcanza's centralized patient recruitment and retention efforts as a complementary services provider in the trial conduct ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alcanza-clinical
• Facebookfacebook.com/Alcanza-Clinical-Research

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alcanza Clinical Research